Physician profile
Lawrence Davis
NPI 1881675098
$3,314.73
in general payments reported to CMS, 2019-2025
29 companies · $1,165 in 2025
The $1,165 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $611 · 2020: $83.38 · 2022: $44.24 · 2023: $546 · 2024: $866 · 2025: $1,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,514 · Education: $62.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,514.06 |
| Education | $62.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $363.76 | 2019-2025 | Farxiga, Lokelma, Breztri |
| Fresenius USA Marketing, INC. | $346.32 | 2019-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $345.80 | 2022-2025 | |
| Amgen INC. | $272.93 | 2019-2025 | Tavneos, Prolia, Evenity |
| Otsuka America Pharmaceutical, INC. | $252.24 | 2019-2025 | Jynarque, Voyxact |
| Calliditas Therapeutics US INC. | $245.94 | 2023-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $225.60 | 2024-2025 | |
| Novo Nordisk INC | $206.68 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Aurinia Pharma U.S., INC. | $150.01 | 2024-2025 | Lupkynis |
| Vifor Pharma, INC. | $128.67 | 2019-2024 | Veltassa, Korsuva |
| Novartis Pharmaceuticals Corporation | $116.42 | 2024-2025 | |
| Ardelyx, INC. | $97.89 | 2024-2025 | Ibsrela |
| Opko Pharmaceuticals, LLC | $95.32 | 2019-2024 | Rayaldee |
| Janssen Pharmaceuticals, INC | $89.37 | 2019-2020 | |
| Lilly USA, LLC | $86.50 | 2019-2024 | Mounjaro, Zepbound |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $47.85 | 2023-2024 | Shingrix, Arexvy, Benlysta |
| Horizon Therapeutics Plc | $38.88 | 2019 | |
| Pfizer INC. | $31.72 | 2019-2024 | |
| Daiichi Sankyo INC. | $25.33 | 2019-2020 | |
| Renalytix Ai, INC. | $17.90 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Ani Pharmaceuticals, INC. | $17.33 | 2023 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.27 | 2023 | Tradjenta, Jardiance |
| Akebia Therapeutics INC | $15.00 | 2019 | |
| Xeris Pharmaceuticals, INC. | $14.91 | 2023 | Keveyis |
| Apellis Pharmaceuticals, INC. | $14.75 | 2025 | Empaveli |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $12.86 | 2019 | |
| Mallinckrodt Hospital Products INC. | $12.80 | 2020 | |
| Merck Sharp & Dohme LLC | $12.50 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.